Chapter 18A – Eligibility at a Glance
Chapter 18A allows pre-revenue biotech companies to list on HKEX provided they can demonstrate advanced clinical progress, credible funding, and sufficient regulatory and governance readiness ahead of a formal application.
Core Product Definition
At least one core product beyond the concept stage, typically supported by Phase I clinical trials that have received regulatory clearance to proceed to Phase II.
Market Capitalisation Threshold
A minimum expected market capitalisation at listing, materially higher than the general Main Board requirement.
Sophisticated Investor Backing
Meaningful third-party investment from at least one sophisticated, unrelated investor prior to listing.
Working Capital Sufficiency
Adequate funding to sustain operations, including the core product’s development, for at least 12 months post-listing.
Primary Business Focus
The company’s primary business must be the research and development of its core product, not solely commercial exploitation.
IP Ownership & Governance
Clear ownership or licensing rights to the intellectual property underpinning the core product, alongside sound corporate governance.
Clinical Stage vs. Regulatory Readiness
Chapter 18A applicants are assessed differently depending on how far their core product has progressed through clinical development and regulatory engagement.
| Criteria | Earlier-Stage Applicant | Later-Stage Applicant |
|---|---|---|
| Clinical Progress | Phase I cleared, entering Phase II | Phase II complete or Phase III underway |
| Regulatory Engagement | Initial regulatory dialogue established | Sustained regulatory engagement with clear milestones |
| Investor Validation | Single sophisticated investor typically sufficient | Broader syndicate of sophisticated investors expected |
How HCCT Group Supports This Pathway
Clinical Milestone Review
Assess whether current trial progress and regulatory dialogue align with Chapter 18A expectations.
Funding & Governance Positioning
Help determine whether working capital, investor backing, and governance structures meet listing readiness standards.
Introductions to Licensed Professionals
Connect clients with SFC-licensed sponsors, clinical experts, and legal counsel experienced in Chapter 18A listings.
Licensed Professionals Coordinations
Coordinate with SFC-licensed sponsors, technical experts, and legal counsel experienced for readiness in Chapter 18B listings.
Where HCCT Group’s Support Adds the Most Value
Chapter 18A due diligence spans clinical credibility and corporate readiness at once. Our role is to help a company present both dimensions clearly before it engages licensed transaction professionals.
Our role is to help a company clarify its sector fit before committing to a listing route, drawing on both financial and technical perspectives to assess where it genuinely stands. We also coordinate between the different professionals involved in a listing, including sponsors, legal counsel, and technical experts, so that the company’s classification, documentation, and funding position remain consistent across every stage of the process.
Indicative Listing Timeline
Chapter 18A listings typically span 9-15 months from readiness assessment to first trading day, depending on clinical data maturity and regulatory engagement.
Readiness Assessment
Review of clinical progress, funding position, and governance structure against Chapter 18A criteria.
Professional Engagement
Introduction to an SFC-licensed sponsor, legal counsel, and clinical experts to begin formal preparation.
Due Diligence & Drafting
Sponsor-led due diligence and preparation of the listing document, alongside continued regulatory engagement.
Regulatory Review
Submission to and review by HKEX and, where applicable, the Securities and Futures Commission.
Listing & First Trading Day
Pricing, allocation, and admission to trading on the Main Board.
A Company-Specific Clinical & Readiness Gap Analysis
Knowing the eligibility criteria is one thing; demonstrating a convincing fit to HKEX and a sponsor is another. A paid consultation produces a formal readiness memo mapping clinical milestones against Chapter 18A requirements, a funding and governance gap analysis based on actual company data, and a shortlist of sponsors matched to the specific therapeutic area.
Book a Paid ConsultationAssess Your Chapter 18A Readiness
Speak with our team about clinical milestones, funding position, and next steps toward a Chapter 18A listing.
Book a ConsultationHCCT Group provides business consulting and introduction services only. We are not licensed by the Securities and Futures Commission (SFC) to advise on corporate finance or securities matters, and nothing on this page constitutes such advice. We help clients identify and connect with appropriately SFC-licensed sponsors, legal counsel, and other regulated professionals required to execute a Chapter 18A listing.